# ltztherapeutics

**Canonical:** https://apis.io/providers/ltztherapeutics/  
**Website:** https://ltztherapeutics.com  
**APIs profiled:** 0

LTZ Therapeutics is a clinical-stage immunotherapy biotechnology company developing novel myeloid engager therapeutics for cancer treatment. Its platform focuses on the direct engagement of myeloid cells with target cells to boost anti-tumor immunity, with lead candidate LTZ-232 receiving FDA IND clearance in July 2026 for advanced metastatic colorectal cancer and other solid tumors. The company operates from Redwood City, USA and Shenzhen, China. It is a portfolio company of Qiming and was added to the API Evangelist network as a stub for enrichment; it publishes no developer API surface.

## Kin Score — 10.6 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 10.6).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 7.1 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Ltztherapeutics Domain Security** — TLSv1.3

## Tags

Company, Biotechnology, Immunotherapy, Oncology, Therapeutics, Pharmaceuticals

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/ltztherapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.